市場調查報告書

全球隱球菌病治療藥市場:成長,趨勢,及預測(2020年∼2025年)

Cryptococcosis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921893
出版日期 內容資訊 英文 113 Pages
商品交期: 2-3個工作天內
價格
全球隱球菌病治療藥市場:成長,趨勢,及預測(2020年∼2025年) Cryptococcosis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 113 Pages
簡介

根據HIV /愛滋病相關聯合國計劃及WHO,在世界中每年約有100萬人的隱球菌症報告,因此導致約62萬5,000人死亡。還有根據疾病管理預防中心與WHO,估計在全世界每年有22萬件HIV / AIDS患者發生隱球菌性腦膜炎,近18萬1,000人死亡。全球隱球菌病治療藥市場,由於盛行率的增加,事前治療的利用可能性,新的先進治療等要素而擴大。但,藥的使用相關的不良影響,可能妨礙該市場成長。

本報告提供全球隱球菌病治療藥市場的相關調查,市場機會和趨勢,成長及阻礙因素,各治療藥、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 致命的真菌病的盛行率增加
    • 有利的償付政策
    • 新的先進治療的機會
  • 市場阻礙因素
    • 治療的副作用
  • 波特的五力分析

第5章 市場區隔

  • 各治療藥物
    • Amphotericin B
    • Flucytosine
    • Fluconazole
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Abbott Laboratories
    • Alkopharma Inc
    • Astellas Pharma Inc
    • Bristol-Myers Squibb Company
    • Glenmark Pharmaceuticals
    • Janssen Biotech Inc. (Johnson & Johnson)
    • Novartis AG
    • Pfizer Inc
    • Sigmapharm Laboratories LLC
    • Valeant Pharmaceuticals Inc

第7章 市場機會及今後趨勢

目錄
Product Code: 67486

Market Overview

Cryptococcosis is a fungal infection which is caused by Cryptococcus neoformans and Cryptococcus gattii which primarily affects the central nervous system and the lungs. People with diseases such as AIDS, Hodgkin lymphoma, other lymphomas, sarcoidosis and solid organ transplantation with weakened immune systems are generally more susceptible to this type of infection. Cryptococcosis is usually acquired by inhalation of dust containing yeast cells which typically affects the lungs. Cryptococcosis symptoms include fever, malaise, cough, hemoptysis (blood or blood-tinged sputum), headache, vision changes (blurry or double vision, photophobia), etc. Cryptococcosis diagnosis is clinical and microscopic, which is confirmed by culture or fixed-tissue staining. According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 deaths approximately. According to the Centers for Disease Control and Prevention and WHO, it is estimated that globally every year 220,000 cases of cryptococcal meningitis occur among people with HIV/AIDS, resulting in nearly 181,000 deaths.

The growing prevalence of cryptococcosis and the availability of advance treatment are the key factors that drive the growth of the cryptococcosis diseases market. However, adverse effects associated with the use of medication is likely to restrain the market growth in the forecast period.

Scope of the Report

Cryptococcosis is a fungal infection which is caused by Cryptococcus neoformans and Cryptococcus gattii which primarily affects the central nervous system and the lungs. Cryptococcosis therapeutics are segmented by Treatment (Amphotericin B, Flucytosine, Fluconazole, others) and Geography.

Key Market Trends

Flucytosine Segment is Expected to Hold a Significant Market Share in the Cryptococcosis Therapeutics

  • Flucytosine is a small, very water-soluble molecule which is a nucleoside analog antifungal drug that acts by disrupting pyrimidine metabolism in the fungal cell nucleus. Flucytosine is generally given as first-line treatment in combination with other antifungal medications.
  • In the year 2016, Flucytosine was a major revenue holding segment because it is given as first-line treatment in combination with other antifungal medications.
  • According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 deaths approximately.
  • Increasing the prevalence of cryptococcosis and increasing new and advanced treatment opportunities are the key factors for the growth of the cryptococcosis market.

North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major share globally in the cryptococcosis market due to the rising prevalence of cryptococcosis, the rise in technological advancements and the higher cost of medication in this region. In the United States prevalence of cryptococcosis is estimated to be about 0.4-1.3 cases per 100,000 population and 2-7 cases per 100,000 in people affected with AIDS with a case fatality ratio of about 12%. In the year 2015, North America hold a highest market share on the global cryptococcosis market. However, the rising prevalence of cryptococcosis in the endemic areas of the United States is fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Cryptococcosis Therapeutics Market is moderately consolidated and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some companies are adopting numerous strategies including acquisitions and collaborations to sustain market competition. Some of the companies which are currently dominating the market are Abbott Laboratories, Alkopharma Inc, Astellas Pharma Inc, Bristol-Myers Squibb Company, Glenmark Pharmaceuticals, Janssen Biotech Inc. (Johnson & Johnson), Novartis AG, Pfizer Inc, Sigmapharm Laboratories LLC, Valeant Pharmaceuticals Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Fatal Fungal Disease
    • 4.2.2 Favorable Reimbursement Policies
    • 4.2.3 New and Advanced Treatment Opportunities
  • 4.3 Market Restraints
    • 4.3.1 Adverse Effects of the Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment
    • 5.1.1 Amphotericin B
    • 5.1.2 Flucytosine
    • 5.1.3 Fluconazole
    • 5.1.4 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Alkopharma Inc
    • 6.1.3 Astellas Pharma Inc
    • 6.1.4 Bristol-Myers Squibb Company
    • 6.1.5 Glenmark Pharmaceuticals
    • 6.1.6 Janssen Biotech Inc. (Johnson & Johnson)
    • 6.1.7 Novartis AG
    • 6.1.8 Pfizer Inc
    • 6.1.9 Sigmapharm Laboratories LLC
    • 6.1.10 Valeant Pharmaceuticals Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS